Carregant...
A Bayesian Adaptive Design for Cancer Phase I Trials Using a Flexible Range of Doses
We present a Bayesian adaptive design for dose finding in cancer phase I clinical trials. The goal is to estimate the maximum tolerated dose (MTD) after possible modification of the dose range during the trial. Parametric models are used to describe the relationship between the dose and the probabil...
Guardat en:
| Publicat a: | J Biopharm Stat |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5832533/ https://ncbi.nlm.nih.gov/pubmed/28858566 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10543406.2017.1372774 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|